Management



Shareholder Tools


Our executive team has over 60 years of combined industry experience, and a proven track record of leadership, global registration, and lifecycle management for over 20 products.

Image of Kenneth J. Hillan M.B. Ch.B.
Dr. Hillan joined Achaogen in 2011 as Chief Medical Officer and was appointed Chief Executive Officer and a member of its board of directors in October 2011. Prior to joining Achaogen, from August 1994 to April 2011, Dr. Hillan served at Genentech, Inc. (acquired by Roche in 2009), a pharmaceutical company. Dr. Hillan was responsible for numerous successful drug approvals and led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio. He served in a number of key leadership positions in research and development, including Senior Vice President Clinical Development, Inflammation, Vice President Immunology, Tissue Growth and Repair (ITGR), Vice President Development Sciences and Vice President Research Operations and Pathology. Dr. Hillan also previously served as Senior Vice President and head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. Dr. Hillan currently serves on the board of directors of Zymeworks, Inc., and he served on the board of directors of Relypsa, Inc. from 2014 until 2016, when it was acquired by Galenica AG.
 
Dr. Hillan has an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, U.K. Dr. Hillan is a Fellow of the Royal College of Surgeons (FRCS), and a Fellow of the Royal College of Pathologists (FRCPath). Dr. Hillan has authored dozens of scientific publications and is a named inventor on almost 50 issued patents.
Image of Blake Wise

Mr. Wise joined Achaogen as Chief Operating Officer in 2015 and, in February 2017 he was appointed President and Chief Operating Officer. Prior to Achaogen, Mr. Wise spent 13 years at Genentech, where he most recently established and led the Cross BioOncology franchise as Vice President, Cross BioOncology. In this role, Mr. Wise spearheaded cross-portfolio oncology initiatives, including key account management, marketing, managed markets, companion diagnostics, pipeline commercialization, and long-term oncology strategy. During his time at Genentech, Mr. Wise also held several other leadership positions of increasing responsibility, including Senior Director, Franchise Head and Life Cycle Leader of the Lytics franchise, with overall commercial responsibility for Genentech’s hospital-based Lytics business. He previously served as a Sales Director in BioOncology, Marketing Director in Cystic Fibrosis and Immunology, and Interactive Marketing Director where he built Genentech’s digital marketing capabilities. Prior to joining Genentech in 2002, Mr. Wise worked in consumer marketing, e-commerce and online marketing outside of the healthcare industry in leadership positions at Gap, Inc. and Webvan. Mr. Wise received a Bachelor of Arts degree in Business Economics from University of California, Santa Barbara, and a Masters of Business Administration degree from University of California, Berkeley, Haas School of Business.

Ms. Bhatt joined Achaogen as Chief Business Officer in 2017. Ms. Bhatt brings to Achaogen more than 20 years of experience in corporate development and strategy in the biopharmaceutical industry. Most recently, Ms. Bhatt held the position of Vice President, Corporate Development at Gilead Sciences where she was responsible for executing licenses, acquisitions and collaborations across all of Gilead’s therapeutic areas. While at Gilead, she also led long-term global commercial and strategic planning for Gilead’s antiviral and respiratory franchises. Before Gilead, Ms. Bhatt held corporate development and strategy roles at Eli Lilly and Maxygen. Ms. Bhatt earned a B.A. in Chemistry from Pomona College, an M.S. in Biomedical Sciences from the University of California at San Diego, and an M.B.A. from the Kellogg School of Management at Northwestern University.

Image of Janet Dorling

Ms. Dorling joined Achaogen as Chief Commercial Officer in 2017. Prior to Achaogen, Ms. Dorling spent 14 years at Genentech and Roche where, as Vice President of Global Product Strategy, Breast Cancer at Roche/Genentech, she was responsible for developing and implementing global commercialization and lifecycle strategies for the Breast Cancer Franchise. Previously, as Vice President of the Lytics Franchise, Ms. Dorling lead hospital-focused Sales and Marketing teams that promoted Activase and Cathflo in the acute care setting. Ms. Dorling also had multiple roles with increasing responsibility in Market Analysis and Strategy in Ophthalmology, Oncology, and ultimately leading multiple functions with portfolio-wide responsibility. Prior to joining Genentech Ms. Dorling had several roles in Business Development at Altus Biologics, DNA Sciences, and Clontech Laboratories. Ms. Dorling has a Bachelor of Arts in Molecular and Cellular Biology from the University of California at Berkeley, a Master's in Science in Pharmacology and Cancer Biology from Duke University, and a Master's in Business Administration from the Haas School of Business at the University of California at Berkeley.

Image of Gary Loeb
Mr. Loeb joined Achaogen in 2016 after more than 15 years of legal affairs experience related to intellectual property, corporate governance, compliance, and business development in the biotechnology industry. Most recently, Mr. Loeb has been General Counsel and Corporate Secretary and on the executive team at three life sciences companies, Amyris, Inc., Counsyl, and most recently Sano Intelligence. Previously, Mr. Loeb spent eleven years at Genentech most recently as Vice President, Intellectual Property, where he oversaw 90 employees in the areas of litigation, patent prosecution, corporate records and technology licensing. 
 
Since 2006, Mr. Loeb has been an adjunct professor at University of San Francisco Law School. He is currently on the Board of Directors for Project Open Hand, a nonprofit organization that provides meals to critically ill neighbors and seniors, and Columbia Law School. Mr. Loeb received a Bachelor of Science degree in Biology and Bachelor of Arts degree in English from Stanford University in California and a Juris Doctor degree from Columbia Law School in New York. He clerked in the Northern District of Texas and, for several years, practiced commercial and intellectual property law in Los Angeles and San Francisco, California.
 
Image of Zeryn Sarpangal

Ms. Sarpangal joined Achaogen in 2009 and is our Senior Vice President of Corporate and People Strategy. She has previously served as Achaogen’s Vice President of Human Resources and Corporate Affairs and, prior to that, as Sr. Director of Finance & Operations and Director of Strategic Marketing. Ms. Sarpangal has prior experience as the Vice President of Finance & Operations at Identified, an HR data analytics company, an engagement manager at McKinsey & Company, a global management consulting firm, and a healthcare investment banking analyst at Goldman, Sachs & Co. She received a Bachelors of Arts in Economics and Molecular & Cell Biology from University of California, Berkeley, and a Masters of Business Administration from the Stanford Graduate School of Business.

Image of Tobin Schilke
Mr. Schilke joined Achaogen in 2016 after 13 years at Roche/Genentech, a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. He most recently was the CFO and Company Director of Roche Products Limited in the United Kingdom. In this role, Mr. Schilke was responsible for financial planning and analysis (FP&A), accounting, legal & financial compliance, supply chain, procurement and site services for Roche’s Pharma presence in the UK. Previously, Mr. Schilke had overall FP&A responsibility for Genentech's Commercial BioOncology business and, prior to Genentech, led a number of successful acquisition and spin-out deals as a member of the Roche Corporate M&A team. Prior to joining Roche/Genentech in 2002, Mr. Schilke was a chemical process development engineer at Monsanto/Pharmacia.
 
Mr. Schilke received a Bachelor of Science degree in Chemical Engineering from Lafayette College in Easton, Pennsylvania, a Masters of Science degree from University of California in Berkeley, California, and a Masters of Business Administration degree from Cornell University’s Johnson Graduate School of Management in Ithaca, New York.
 
Image of Lee Swem Ph.D.

Dr. Swem was appointed Chief Scientific Officer in February 2017 and, prior to that, was the Vice President, Head of Research at Achaogen since 2015. Prior to this position, Dr. Swem spent just under two years as the Director of Achaogen’s Therapeutic Antibody Program, where he developed a state-of-the-art antibody discovery platform to rapidly identify rare functional antibodies to treat serious human infectious diseases. Before joining Achaogen, Dr. Swem spent approximately four years as a Scientist in the Department of Infectious Disease at Genentech. During his tenure at Genentech, he developed the anti-influenza A program, the anti-influenza B program, and began a small molecule anti-bacterial program. Under his leadership, the anti-influenza teams established an innovative human B cell enrichment and cloning technique to discover rare functional antibodies. This work led to the discovery of two broadly neutralizing antibodies targeting influenza A  and influenza B.Dr. Swem served as the research lead on the anti-influenza development teams, which successfully transitioned the anti-influenza A antibody  through Phase 1 and Phase 2 clinical trials and the anti-influenza B antibody into early development. The combination of these two human antibodies could constitute a therapy to treat all serious influenza infections. Prior to working at Genentech, Dr. Swem completed his postdoctoral work with Dr. Bonnie Bassler at Princeton University, where he successfully carried out multiple high-throughput screens to identify small molecule inhibitors of bacterial virulence cascades. Dr. Swem received his Ph.D. in microbiology from Indiana University.